Clinical trials: Human Papillomavirus Vaccines
Human Papilloma Virus, Anal Dysplasia
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen…
- Conditions
- Human Papilloma Virus, Anal Dysplasia, HIV
- Trial name
- PROTECT (NCT06624839)
- Testing
- Human papillomavirus (HPV) vaccine, 9-valent
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HPV Vaccine
Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy
The goal of this clinical trial is to learn if a chatbot powered by artificial intelligence works to improve HPV vaccination among females aged 15 to 45 in China.
- Trial name
- NCT07200570
- Testing
- LLM-Powered HPV Vaccine Chatbot
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Fudan University
Immunization, Vaccination
The STOP-HPV Trial 1: Communication Intervention
Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates.
- Trial name
- STOP-HPV (NCT03599557)
- Testing
- STOP-HPV communication intervention
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HPV, High-risk HPV (Any Strain)
Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV
This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16/18/31/33/45/52 or 58 can decrease the infectivity of shed…
- Conditions
- HPV, High-risk HPV (Any Strain), Human Papillomavirus (HPV) Infections
- Trial name
- RIFT-SSA (NCT07303751)
- Testing
- Nonavalent HPV vaccine (9vHPV)
- Where
- Sierra Leone
- Volunteers
- 80 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Human Papillomavirus Infection
Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).
- Trial name
- NCT01702337
- Testing
- Prevalence-based model
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine.
- Trial name
- NCT01461993
- Testing
- rLP2086 and Gardasil, rLP2086, Gardasil
- Where
- 87 sites in United States
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Papillomavirus
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated with human papillomavirus…
- Trial name
- NCT00929526
- Testing
- Liquid-based cytology (LBC) sampling, Blood sampling
- Where
- 13 sites in Japan
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Warts
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for…
- Trial name
- NCT05625633
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Western Institute for Veterans Research
Neoplasia
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
The researchers involved in this new study are interested in whether giving a HPV vaccine to women at the same time as conisation can lead to a greater rate of HPV clearance compared to conisation on its own, and a result reduce…
- Trial name
- NOVEL (NCT03979014)
- Testing
- Gardasill 9™ vaccine
- Where
- 13 sites in Finland, Sweden and 1 more
- Volunteers
- 1,099 people
- Sponsor
- Imperial College London
Papillomavirus Vaccines
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused…
- Trial name
- NCT04469569
- Testing
- HPV-PROTECT
- Where
- 6 sites in United States
- Volunteers
- 8,120 people
- Sponsor
- University of Alabama at Birmingham
Human Papillomavirus
Tailoring of Vaccine-Focused Messages: Disease Salience
This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and…
- Trial name
- NCT03002324
- Testing
- Baseline Survey, Current CDC Message, Cervical Cancer Message
- Where
- United States
- Volunteers
- 1,320 people, healthy volunteers welcome
- Sponsor
- Emory University
Vaccine Refusal
Optimizing HPV Vaccine Introduction in Shanghai, China
Within low, middle, and upper income countries, low vaccine coverage results from both obstacles to vaccine access and low confidence in vaccine programs.
- Trial name
- NCT03972813
- Testing
- Broadened information about cancers, Information about STDs, Information about infectious disease
- Where
- China
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Human Papillomavirus Infection, Vaccination Hesitancy
Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy
Since 2019, the HPV working group of the University of Virginia Cancer Center's Southwest Virginia Community Advisory Board has developed and executed strategies to increase regional HPV vaccination rates.
- Trial name
- NCT05860725
- Testing
- PSA Development, HPV vaccination focused social marketing campaign
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Virginia
HPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia
It is possible that achieving adequate HPV vaccination coverage will allow cervical cancer to be virtually eliminated. This is a priority for Georgia, where the burden of mortality and morbidity from cervical cancer is high and…
- Trial name
- NCT05536674
- Testing
- SMS reminder for the HPV vaccination
- Volunteers
- 55,176 people, healthy volunteers welcome
- Sponsor
- The Behavioural Insights Team
HPV Vaccination
Evaluation of the Implementation and Effectiveness of IPP-HPV
The purpose of the proposed pilot study is to assess the implementation of IPP-HPV immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and facilitators of this intervention to optimize its…
- Trial name
- NCT02994290
- Testing
- HPV vaccine, Inpatient Postpartum HPV Immunization Quality Improvement Program
- Where
- United States
- Volunteers
- 817 people
- Sponsor
- Yale University
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
- Trial name
- NCT00054041
- Testing
- HspE7, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Papilloma of the Larynx
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis
Vaccines against human papillomaviruses are now commercially available. One of the commercial vaccine contains antigens of both LR HPV types which cause virtually all cases of RRP.
- Trial name
- NCT01375868
- Testing
- Silgard
- Where
- Czechia
- Volunteers
- 51 people
- Sponsor
- Ruth Tachezy, PhD.
Papillomavirus Vaccines, HPV Vaccinations
HPV Vaccine Integrated Service Implementation Research in Cameroon
The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls and…
- Conditions
- Papillomavirus Vaccines, HPV Vaccinations, HPV Vaccines, HPV Vaccine Acceptability
- Trial name
- HPV-PASSREV (NCT06683664)
- Testing
- Integrated health service delivery for very young adolescents
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Population Services International
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00520598
- Testing
- Comparator: V505 formulation 1, Comparator: V505 formulation 2, Comparator: V505 formulation 3
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC